Brand-name drug patent expirations 2024-2028, generic entry timing, and per-drug savings on substitution.
The fields present on each record, named exactly as they appear in the data, so a query written against this list will run.
Released under CC BY 4.0. You may use it commercially and redistribute it. Attribution is the only condition.
Couey, V. W. (2026). Brand-to-Generic Patent Cliff 2026. Deep Synthesis. https://doi.org/10.5281/zenodo.20632747
FDA CAERS-derived adverse event reports for dietary supplements over a decade: ingredient category, severity, outcome, year. Modeled estimates.
Pharmacy benefit manager spread economics: NADAC reference price vs reimbursed price vs plan-paid price across high-volume generics.